Clay Siegall, Ph.D., the CEO of Immunome, has a wealth of experience in biotechnology. He carries a Ph.D. in Genetics from George Washington University and co-founded Seagen, Inc., where he was the CEO for nearly two decades. His leadership there...

Clay Siegall, Ph.D., the CEO of Immunome, has a wealth of experience in biotechnology. He carries a Ph.D. in Genetics from George Washington University and co-founded Seagen, Inc., where he was the CEO for nearly two decades. His leadership there helped shape the company until its recent acquisition by Pfizer. Dr. Siegall joined Immunome in 2023 following the merger with Morphimmune, where he served as CEO. His role now includes driving the company’s vision and ensuring it meets performance goals. In 2023, he received a salary of $162,500, along with a performance bonus of $483,600, showing his interests align with the company’s success. Additionally, he was granted stock options to buy over 2 million shares, which is contingent on his continued employment. Dr. Siegall’s journey reflects a strong commitment to advancing cancer treatments through biotechnology and a focus on research and development, setting the stage for Immunome's strategic growth in the industry.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

I

Clay Siegall, Ph.D.

Founder and CEO of Immunome

Education

Ph.D. in Genetics from George Washington University

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1960 - 65 years ago

CEO of Immunome for

1 year 8 months (Oct 2023 - Present)

Previous Experience

Co-founded Seagen, Inc. and served as CEO from November 2002 to May 2022.

Rivals

Competitors/colleagues of Clay Siegall, Ph.D.

Holdings

See how much did Clay Siegall, Ph.D. make over time.

Clay Siegall holds a significant investment in Immunome. In 2023, he received stock options for 2,137,080 shares, which vest over four years if he remains with the company. This grant highlights his strong belief in Immunome’s future and aligns his...

Clay Siegall holds a significant investment in Immunome. In 2023, he received stock options for 2,137,080 shares, which vest over four years if he remains with the company. This grant highlights his strong belief in Immunome’s future and aligns his interests with the company's performance. Notably, his wealth largely depends on the success of these stock options, as no other reported vested stocks indicate his commitment. His previous experience at Seagen reflected this kind of alignment; the values of his holdings soared during pivotal phases of growth there. Given his extensive background in biotech, he likely understands how to navigate the complexities of such investments, making him a key figure in Immunome’s potential success.

Mar 18, 2025

R

shares

RARE @ $38.86

Total Stock Sold

$2.95M

RARE

$2.95M

34,750 RARE shares

What if they kept their stock?

If Clay Siegall, Ph.D. didn't sell their stock, today they would have:
Extra RARE34,750 shares worth $2.37M.
This is -19.87% and $586.62K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Clay Siegall, Ph.D..

RARE

$2.96M

RARE at $85.19/share

Aug 7, 2020

Sale

RARE

2,550 shares

RARE

Jun 26, 2020

Received

RARE

3,000 shares

RARE

Jun 11, 2019

Received

RARE

3,000 shares

RARE

Jun 19, 2018

Received

RARE

1,875 shares

RARE

Jun 22, 2017

Received

RARE

1,875 shares

RARE

Jun 9, 2016

Received

Compensation History

See how much did Clay Siegall, Ph.D. make over time.

In 2023, Dr. Clay Siegall's total compensation was significant yet reflects both his role and the company's performance. He earned a base salary of $162,500, which is just a part of his overall package. His performance bonus added $483,600, indicating a successful year in achieving corporate goals. He didn't receive any vested stock in 2023, but he did receive stock options that can greatly increase his wealth depending on the company's performance in the future. His compensation plan is structured to motivate him to align his efforts with the company's interests, grounding his potential earnings in actual performance. This shows he has a stake in the company's long-term success and aligns with shareholders' interests.

Year

2023

Total Compensation

$650.98K

Salary

$162.50K

Board Justification

Compensation aligns with company performance, peer benchmarking, and retention strategies, with target cash compensation referencing the 50th percentile of peer group and equity compensation at the 75th percentile.

Bonus

$483.60K

Board Justification

Annual performance bonus based on achievement of Company-wide performance goals, credited with time employed by Morphimmune during calendar year 2023.

Other

$4.88K

Board Justification

401(k) plan employer matching contributions.

Restricted Stock

$0.00(0 N/A)

Board Justification

No vested stock reported for 2023.

Performance Metrics

Performance metrics for 2023 included research, development, and corporate objectives.